1245 related articles for article (PubMed ID: 16963204)
1. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Jeon YT; Kang S; Kang DH; Yoo KY; Park IA; Bang YJ; Kim JW; Park NH; Kang SB; Lee HP; Song YS
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1538-42. PubMed ID: 15342458
[TBL] [Abstract][Full Text] [Related]
3. Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy.
Antunes A; Costa-Paiva L; Arthuso M; Costa JV; Pinto-Neto AM
Maturitas; 2007 Aug; 57(4):415-21. PubMed ID: 17587515
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium.
Farrell R; Scurry J; Otton G; Hacker NF
Gynecol Oncol; 2005 Aug; 98(2):254-62. PubMed ID: 15936803
[TBL] [Abstract][Full Text] [Related]
5. The association between p53 expression, stage and histological features in endometrial cancer.
Ragni N; Ferrero S; Prefumo F; Muschiato B; Gorlero F; Gualco M; Fulcheri E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):111-6. PubMed ID: 15894417
[TBL] [Abstract][Full Text] [Related]
6. Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases.
Trahan S; Têtu B; Raymond PE
Hum Pathol; 2005 Dec; 36(12):1316-21. PubMed ID: 16311126
[TBL] [Abstract][Full Text] [Related]
7. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
8. Clinical parameters linked with malignancy in endometrial polyps.
Gregoriou O; Konidaris S; Vrachnis N; Bakalianou K; Salakos N; Papadias K; Kondi-Pafiti A; Creatsas G
Climacteric; 2009 Oct; 12(5):454-8. PubMed ID: 19591006
[TBL] [Abstract][Full Text] [Related]
9. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
10. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
11. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
12. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
13. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
14. The risk of premalignant and malignant pathology in endometrial polyps.
Bakour SH; Khan KS; Gupta JK
Acta Obstet Gynecol Scand; 2000 Apr; 79(4):317-20. PubMed ID: 10746849
[TBL] [Abstract][Full Text] [Related]
15. Is the immunohistochemical expression of proliferation (Ki-67) and apoptosis (Bcl-2) markers and cyclooxigenase-2 (COX-2) related to carcinogenesis in postmenopausal endometrial polyps?
Antunes A; Andrade LA; Pinto GA; Leão R; Pinto-Neto AM; Costa-Paiva L
Anal Quant Cytopathol Histpathol; 2012 Oct; 34(5):264-72. PubMed ID: 23301386
[TBL] [Abstract][Full Text] [Related]
16. Proliferation in Postmenopausal Endometrial Polyps-A Potential for Malignant Transformation.
Adomaitienė L; Nadišauskienė R; Nickkho-Amiry M; Čižauskas A; Palubinskienė J; Holland C; Seif MW
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31466367
[No Abstract] [Full Text] [Related]
17. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy.
Graesslin O; Chantot-Bastaraud S; Lorenzato M; Birembaut P; Quéreux C; Daraï E
Ann Surg Oncol; 2008 Feb; 15(2):484-92. PubMed ID: 18071824
[TBL] [Abstract][Full Text] [Related]
19. Expression of mTOR protein and its clinical significance in endometrial cancer.
No JH; Jeon YT; Park IA; Kang D; Kim JW; Park NH; Kang SB; Song YS
Med Sci Monit; 2009 Oct; 15(10):BR301-305. PubMed ID: 19789507
[TBL] [Abstract][Full Text] [Related]
20. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients.
Cohen I; Bernheim J; Azaria R; Tepper R; Sharony R; Beyth Y
Gynecol Oncol; 1999 Oct; 75(1):136-41. PubMed ID: 10502440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
